ONC
BeOne Medicines Ltd.
ONC has the edge over OSCR overall, supported by lower modeled downside and stronger fundamentals.
OSCR
Oscar Health, Inc.
OSCR offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
ONC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
ONC's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ONC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 52x | $416 | — |
| Cheap | 62x | $37.70 | -91% |
| Fair | 72x | $43.95 | -89% |
| Expensive | 650x | $396 | -4.8% |
Historical ranges are pointers, not guarantees.
ONC's PE is 52x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ONC in the historical PE scenario, which offers more potential upside but is not a forecast.
ONC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for ONC, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ONC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.61 | +1425% |
| Q2 2026 | $0.44 | +$0.57 |
| Q1 2026 | $0.34 | +$0.62 |
| Q4 2025 | $0.19 | +$0.66 |
| Q3 2025 | $0.04 | +$0.67 |
| Q2 2025 | -$0.13 | +$0.26 |
| Q1 2025 | -$0.28 | +$0.30 |
| Q4 2024 | -$0.47 | +$0.18 |
ONC has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ONC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +34% |
| Q2 2026 | $1.7B | +30% |
| Q1 2026 | $1.5B | +35% |
| Q4 2025 | $1.5B | +33% |
| Q3 2025 | $1.4B | +41% |
| Q2 2025 | $1.3B | +42% |
| Q1 2025 | $1.1B | +49% |
| Q4 2024 | $1.1B | +78% |
ONC's revenue has grown year over year for 18 quarters in a row: $1.9B last quarter, up 34% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 22% | +11 points |
| Q2 2026 | 19% | +12 points |
| Q1 2026 | 17% | +16 points |
| Q4 2025 | 12% | +19 points |
| Q3 2025 | 12% | +24 points |
| Q2 2025 | 6.7% | +18 points |
| Q1 2025 | 1% | +36 points |
| Q4 2024 | -7% | +54 points |
ONC has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ONC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ONC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $473.5M | +34% |
| Q2 2026 | $435.3M | +98% |
| Q1 2026 | $160.5M | +$172.9M |
| Q4 2025 | $379.8M | +$397.1M |
| Q3 2025 | $354.5M | +548% |
| Q2 2025 | $219.8M | +$425.3M |
| Q1 2025 | -$12.3M | +$452.8M |
| Q4 2024 | -$17.3M | +$361.3M |
ONC has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ONC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +19.6M shares |
| 1 year | +2.4% | +36.2M shares |
| 3 years | +9.7% | +135M shares |
| 5 years | +26% | +319M shares |
| Available history | +52% | +520M shares |
ONC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ONC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -3.4x | Net Cash |
| Q2 2026 | -3.7x | Net Cash |
| Q1 2026 | -4.4x | Net Cash |
| Q4 2025 | -6.0x | Net Cash |
| Q3 2025 | -9.5x | Net Cash |
| Q2 2025 | -20.2x | Net Cash |
ONC has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ONC on leverage, with a lower net debt burden relative to earnings.
ONC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.6 | Overbought |
| Stochastic | 87.7 | Overbought |
ONC's weekly RSI is 71 (overbought) and its Stochastic is 88 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ONC PE vs Healthcare Sector
| Metric | ONC | Sector median | Relative |
|---|---|---|---|
| PE | 52x | 26x | 103% above |
| PE % | 2 | 29 | 27 pts below |
ONC is trading at 52x earnings, a 103% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ONC on valuation relative to its sector.
ONC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $376.7 | 10% above |
| 20 week MA | $352.8 | 18% above |
| 50 week MA | $326.9 | 27% above |
| 100 week MA | $298.0 | 40% above |
| 200 week MA | $244.9 | 70% above |
ONC is in an uptrend: it's above all five of its weekly moving averages, and 70% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
ONC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $167.2 | $263.7 | +58% |
| 2021 | $263.7 | $268.6 | +1.9% |
| 2022 | $268.6 | $226.1 | -16% |
| 2023 | $226.1 | $180.4 | -20% |
| 2024 | $180.4 | $181.9 | +0.8% |
| 2025 | $181.9 | $312.4 | +72% |
| 2026 YTD | $312.4 | $416.0 | +33% |
ONC has finished higher in four of the last six years, two of them by more than 50%. It's up 33% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ONC on returns for 2026, with the stronger performance.